MYD88 and diffuse large B-cell lymphoma: Zhou et al. analyzed 9 EBV+ and 6 EBV − DLBCL cases by NGS, and they reported MYC, RHOA, PIM1, MEF2B, MYD88, and CD79B mutations in about 25% of EBV + DLBCL, compared with KMT2D, CREBBP, PIM1, TNFAIP3, and BCL2 mutations observed in 35–65% of EBV − DLBCL cases [77].